Resurrected cancer drug faces regulators

Nature. 2014 Jun 26;510(7506):454. doi: 10.1038/510454a.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Benzamides / therapeutic use
  • Clinical Trials as Topic
  • DNA Repair / genetics
  • Drug Approval*
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Humans
  • Indoles / therapeutic use
  • Mice
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics
  • Phthalazines* / pharmacology
  • Phthalazines* / therapeutic use
  • Piperazines* / pharmacology
  • Piperazines* / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases / metabolism
  • Survival Analysis
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Indoles
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • iniparib
  • rucaparib
  • Poly(ADP-ribose) Polymerases
  • olaparib